Grace Therapeutics, Inc. (NASDAQ:GRCE) Short Interest Update

Grace Therapeutics, Inc. (NASDAQ:GRCE) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 31,816 shares, a growth of 31.0% from the December 15th total of 24,289 shares. Currently, 0.2% of the company’s shares are sold short. Based on an average daily trading volume, of 68,338 shares, the short-interest ratio is presently 0.5 days. Based on an average daily trading volume, of 68,338 shares, the short-interest ratio is presently 0.5 days. Currently, 0.2% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Grace Therapeutics in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $12.00.

Institutional Investors Weigh In On Grace Therapeutics

Several hedge funds have recently bought and sold shares of GRCE. Palumbo Wealth Management LLC acquired a new position in shares of Grace Therapeutics in the 2nd quarter valued at $144,000. Millington Financial Advisors LLC bought a new position in Grace Therapeutics during the second quarter worth about $59,000. SeaCrest Wealth Management LLC acquired a new position in Grace Therapeutics in the third quarter valued at about $42,000. Finally, ADAR1 Capital Management LLC grew its stake in Grace Therapeutics by 98.4% in the third quarter. ADAR1 Capital Management LLC now owns 350,450 shares of the company’s stock valued at $1,043,000 after acquiring an additional 173,823 shares during the period. 6.08% of the stock is currently owned by institutional investors and hedge funds.

Grace Therapeutics Stock Up 0.3%

NASDAQ GRCE traded up $0.01 on Friday, reaching $3.65. The company had a trading volume of 48,962 shares, compared to its average volume of 108,414. Grace Therapeutics has a 52 week low of $1.75 and a 52 week high of $4.00. The stock’s 50 day moving average is $3.34 and its 200-day moving average is $3.20. The stock has a market cap of $56.48 million, a price-to-earnings ratio of -5.89 and a beta of 0.55.

Grace Therapeutics (NASDAQ:GRCE) last posted its earnings results on Thursday, November 13th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.03). As a group, analysts forecast that Grace Therapeutics will post -1.06 EPS for the current year.

Grace Therapeutics Company Profile

Grace Therapeutics, Inc (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions.